Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX

Focus Partners Advisor Solutions LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 152.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,263 shares of the company’s stock after purchasing an additional 8,011 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Neurocrine Biosciences were worth $1,945,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in Neurocrine Biosciences by 36.7% in the 1st quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after purchasing an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Neurocrine Biosciences by 60.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after purchasing an additional 5,577 shares during the last quarter. NewEdge Advisors LLC grew its stake in Neurocrine Biosciences by 56.3% in the first quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after purchasing an additional 2,747 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $1,333,000. Finally, Geneos Wealth Management Inc. increased its holdings in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Down 2.8%

Shares of NASDAQ NBIX opened at $129.64 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $160.18. The company’s fifty day simple moving average is $134.66 and its 200 day simple moving average is $140.44. The firm has a market cap of $13.01 billion, a PE ratio of 27.82, a P/E/G ratio of 0.70 and a beta of 0.32.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.69 EPS. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wedbush lifted their target price on Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. HC Wainwright lowered their price target on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. JPMorgan Chase & Co. dropped their price objective on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. UBS Group dropped their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, TD Cowen raised their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.05.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the completion of the sale, the director directly owned 6,239 shares of the company’s stock, valued at $967,606.51. This represents a 16.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 46,966 shares of company stock valued at $6,474,616. Corporate insiders own 4.80% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.